In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.
Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.